Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Gilead AIDS Drug on Par with Raltegravir

By Drug Discovery Trends Editor | July 21, 2011

Gilead Sciences, Inc. announced Phase 3 clinical trial results from the pivotal Study 145 showing that its investigational antiretroviral elvitegravir, a novel oral integrase inhibitor being evaluated for the treatment of HIV-1 infection, was non-inferior to the integrase inhibitor raltegravir after 48 weeks of therapy in treatment-experienced patients. In the study, elvitegravir (150 mg or 85 mg) dosed once daily was compared to raltegravir (400 mg) dosed twice daily. Each integrase inhibitor was administered with a background regimen that included a ritonavir-boosted protease inhibitor (PI) and a second antiretroviral (ARV). These data are being presented in a late-breaker session at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) in Rome, Italy.

“Because many treatment-experienced HIV patients have developed resistance to currently available antiretrovirals, identifying novel therapeutic options from the integrase inhibitor class is critical,” said Professor Jean-Michel Molina, MD, PhD, principal investigator, Hôpital Saint Louis in Paris and University of Paris 7. “These data suggest that elvitegravir may be an effective option for patients and may also have the potential for more convenient, once-daily dosing as part of combination HIV therapy.”

At 48 weeks of treatment in Study 145, 59 percent of patients receiving ritonavir-boosted elvitegravir achieved and maintained HIV RNA levels (viral load) of less than 50 copies/mL, compared to 58 percent of patients receiving raltegravir, based on the Time to Loss of Virologic Response algorithm (TLOVR). Discontinuation rates due to adverse events, and safety and resistance profiles were comparable in both arms of the study.

“These data are an important component of the regulatory filings for elvitegravir as both a stand-alone product and as part of the Quad single-tablet regimen in the United States and Europe in 2012,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “We believe elvitegravir, cobicistat and the Quad have the potential to be important new components of HIV therapy.”

Gilead’s investigational fixed-dose, single-tablet Quad regimen, which is currently in two Phase 3 studies, contains four Gilead compounds in a single pill: elvitegravir; cobicistat, an investigational pharmacoenhancing or “boosting” agent that increases blood levels of certain HIV medicines; Viread (tenofovir disoproxil fumarate); and Emtriva (emtricitabine). Phase 3 study results are expected in the third quarter of this year.

Date: July 20, 2011
Source: Gilead Sciences, Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE